
    
      To determine whether Ozurdex implant can offer an efficacious alternative for treatment of
      macular edema in the setting of retinal vein occlusion when treatment with intravitreal
      bevacizumab (Avastin),ranibizumab (Lucentis), and/or aflibercept (Eylea) have not
      demonstrated significant response.
    
  